Allergy Therapeutics (LON:AGY) Sets New 1-Year High – What’s Next?

Allergy Therapeutics plc (LON:AGY) shares hit a new 52-week high during trading on Monday . The company traded as high as GBX 6.34 ($0.08) and last traded at GBX 5.70 ($0.07), with a volume of 973787 shares traded. The stock had previously closed at GBX 5.50 ($0.07).

Allergy Therapeutics Price Performance

The firm has a 50 day moving average of GBX 5.05 and a two-hundred day moving average of GBX 4.84. The company has a market cap of £271.89 million, a PE ratio of -86.67, a P/E/G ratio of -30.70 and a beta of 1.40. The company has a current ratio of 1.40, a quick ratio of 1.48 and a debt-to-equity ratio of 37.22.

About Allergy Therapeutics

Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics.